A British court rejected Kellogg's arguments in its legal action against the UK government over new regulations preventing it from prominently displaying some of its breakfast cereals in supermarkets due to their sugar content.
Kellogg argued that the UK government's way of measuring the nutritional value of cereal without milk or yogurt is “wrong”.
The new regulations, which come into effect in October, are designed to help tackle childhood obesity and will restrict the promotion of food and drink products that are high in fat, salt, or sugar.
Kellogg noted that it supported the government’s work to tackle obesity, demonstrated by its past efforts to reduce sugar and salt in its cereals.
A Kellogg spokesperson said that while they respect the court's decision and do not intend to appeal, they still believe that cereals should be measured with milk as it is the way most people eat them.
They also raised their concern that the government introduced these regulations without proper parliamentary scrutiny.


TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
China Overturns Death Sentence of Canadian Robert Schellenberg, Signaling Thaw in Canada-China Relations
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 



